ProKidney [PROK] vs Dyne Therapeutics [DYN] Detailed Stock Comparison
ProKidney
NASDAQ
Loading...
Dyne Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: ProKidney wins in 10 metrics, Dyne Therapeutics wins in 3 metrics, with 2 ties. ProKidney appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | ProKidney | Dyne Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.42 | -3.88 | ProKidney |
| Price-to-Book Ratio | 1.06 | 2.50 | ProKidney |
| Debt-to-Equity Ratio | 1.30 | 21.19 | ProKidney |
| PEG Ratio | 0.24 | -0.10 | Dyne Therapeutics |
| EV/EBITDA | -8.38 | -2.77 | ProKidney |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | -17,967.87% | 0.00% | Dyne Therapeutics |
| Return on Equity | -40.52% | -61.32% | ProKidney |
| Return on Assets (TTM) | -25.30% | -35.45% | ProKidney |
| Free Cash Flow (TTM) | $-155.86M | $-294.75M | ProKidney |
| Dividend Yield | 305.81% | N/A | N/A |
| 1-Year Return | 61.18% | -59.91% | ProKidney |
| Price-to-Sales Ratio (TTM) | 1,552.38 | N/A | N/A |
| Enterprise Value | $1.43B | $1.22B | ProKidney |
| EV/Revenue Ratio | 2,707.64 | N/A | N/A |
| Revenue per Share (TTM) | $0 | $0 | Tie |
| Earnings per Share (Diluted) | $-0.56 | $-3.83 | ProKidney |
| Beta (Stock Volatility) | 1.78 | 1.08 | Dyne Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
ProKidney vs Dyne Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ProKidney | -1.44% | 10.04% | 16.10% | 328.13% | 285.92% | 58.38% |
| Dyne Therapeutics | 4.06% | -0.68% | -3.12% | 49.09% | 38.64% | -48.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ProKidney | 61.18% | -71.04% | -72.74% | -72.74% | -72.74% | -72.74% |
| Dyne Therapeutics | -59.91% | 2.67% | -29.94% | -42.72% | -42.72% | -42.72% |
News Based Sentiment: ProKidney vs Dyne Therapeutics
ProKidney
News based Sentiment: MIXED
ProKidney experienced significant price fluctuations and conflicting analyst ratings during October 2025. While speculative buying drove up the stock price, insider selling and a downgraded rating from Bank of America create a mixed investment picture. The lack of fundamental news driving these movements adds to the uncertainty.
Dyne Therapeutics
News based Sentiment: POSITIVE
October was a strong month for Dyne Therapeutics, highlighted by key regulatory approvals (FDA Breakthrough Therapy and Japanese Orphan Drug designation) for DYNE-251, coupled with positive analyst upgrades and insider buying activity. While the company remains pre-revenue, these developments signal significant progress and potential for future growth, making it a noteworthy investment story.
Performance & Financial Health Analysis: ProKidney vs Dyne Therapeutics
| Metric | PROK | DYN |
|---|---|---|
| Market Information | ||
| Market Cap | $806.33M | $1.95B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,296,280 | 2,974,480 |
| 90 Day Avg. Volume | 1,987,337 | 2,474,543 |
| Last Close | $2.74 | $13.06 |
| 52 Week Range | $0.46 - $7.13 | $6.36 - $35.90 |
| % from 52W High | -61.57% | -63.62% |
| All-Time High | $14.19 (Mar 13, 2023) | $47.45 (Aug 19, 2024) |
| % from All-Time High | -80.69% | -72.48% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -179.68% | 0.00% |
| Return on Equity (TTM) | -0.41% | -0.61% |
| Debt to Equity (MRQ) | 1.30 | 21.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-7.51 | $5.00 |
| Cash per Share (MRQ) | $2.18 | $4.81 |
| Operating Cash Flow (TTM) | $-114,420,000 | $-359,560,000 |
| Levered Free Cash Flow (TTM) | $-112,575,248 | $-222,398,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 305.81% | N/A |
| Last 12-Month Dividend | $2.63 | N/A |
Valuation & Enterprise Metrics Analysis: ProKidney vs Dyne Therapeutics
| Metric | PROK | DYN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.42 | -3.88 |
| Forward P/E | -5.45 | -3.96 |
| PEG Ratio | 0.24 | -0.10 |
| Price to Sales (TTM) | 1,552.38 | N/A |
| Price to Book (MRQ) | 1.06 | 2.50 |
| Market Capitalization | ||
| Market Capitalization | $806.33M | $1.95B |
| Enterprise Value | $1.43B | $1.22B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2,707.64 | N/A |
| Enterprise to EBITDA | -8.38 | -2.77 |
| Risk & Other Metrics | ||
| Beta | 1.78 | 1.08 |
| Book Value per Share (MRQ) | $-7.51 | $5.00 |
Financial Statements Comparison: ProKidney vs Dyne Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PROK | DYN |
|---|---|---|
| Revenue/Sales | $230,000 | $0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | $27.26M | $99.24M |
| Operating Income (EBIT) | $-41.39M | $-115.79M |
| EBITDA | $-35.76M | $-110.26M |
| Pre-Tax Income | $-37.36M | $-110.86M |
| Income Tax | $591,000 | N/A |
| Net Income (Profit) | $-37.95M | $-110.86M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PROK | DYN |
|---|---|---|
| Cash & Equivalents | $97.81M | $472.26M |
| Total Current Assets | $359.66M | $689.50M |
| Total Current Liabilities | $32.81M | $33.88M |
| Long-Term Debt | $2.51M | $18.22M |
| Total Shareholders Equity | $369.98M | $668.97M |
| Retained Earnings | $-1.22B | $-1.07B |
| Property, Plant & Equipment | $3.07M | $34.19M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PROK | DYN |
|---|---|---|
| Operating Cash Flow | $-35.14M | $-110.37M |
| Capital Expenditures | $-1.14M | $-981,000 |
| Free Cash Flow | $-30.73M | $-106.87M |
| Debt Repayment | $-12,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PROK | DYN |
|---|---|---|
| Shares Short | 10.12M | 15.30M |
| Short Ratio | 4.23 | 6.78 |
| Short % of Float | 0.11% | 0.12% |
| Average Daily Volume (10 Day) | 1,296,280 | 2,974,480 |
| Average Daily Volume (90 Day) | 1,987,337 | 2,474,543 |
| Shares Outstanding | 128.05M | 102.32M |
| Float Shares | 86.72M | 122.63M |
| % Held by Insiders | 0.27% | 0.00% |
| % Held by Institutions | 0.30% | 0.95% |
Dividend Analysis & Yield Comparison: ProKidney vs Dyne Therapeutics
| Metric | PROK | DYN |
|---|---|---|
| Last 12-Month Dividend | $2.63 | N/A |
| Last 12-Month Dividend Yield | 305.81% | N/A |
| 3-Year Avg Annual Dividend | $3.15 | N/A |
| 3-Year Avg Dividend Yield | 36.48% | N/A |
| 3-Year Total Dividends | $9.44 | N/A |
| Ex-Dividend Date | Feb 14, 2025 | N/A |